Inspire Initiates Special Protocol Assessment Process For Prolacria? Trial For Dry Eye

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has submitted a clinical protocol and request for Special Protocol Assessment (SPA) to the U.S. Food and Drug Administration (FDA) for a pivotal Phase 3 environmental trial with Prolacria? (diquafosol tetrasodium ophthalmic solution) for the treatment of dry eye disease.

More: continued here

Filed under: Eye Health on October 1st, 2008